Search

Displaying results 2691 - 2700 of 5900 in total
  1. Drug

    Propanoic acid

    go.drugbank.com/drugs/DB03766
    ApprovedInvestigationalVet approvedWithdrawn

    Sodium propionate was previously approved in Canada as an active ingredient in Amino-Cerv (used to treat inflammation or injury of the cervix).

  2. Drug

    Acetohexamide

    go.drugbank.com/drugs/DB00414
    ApprovedWithdrawn

    A sulfonylurea hypoglycemic agent that is metabolized in the liver to 1-hydrohexamide. Acetohexamide has been discontinued in the US market.

  3. Drug

    Estradiol benzoate

    go.drugbank.com/drugs/DB13953
    ApprovedVet approvedWithdrawn

    Esterification of estradiol aims to improves absorption and bioavailability after oral administration (such as with Estradiol valerate) or to sustain release from depot intramuscular injections (such as … Ester pro-drugs of estradiol are therefore considered to be bioidentical forms of estrogen [T84]. Estradiol benzoate is not currently available in Canada or the US.

  4. Drug

    Cephaloglycin

    go.drugbank.com/drugs/DB00689
    Approved

    A cephalorsporin antibiotic that is no longer commonly used.

  5. Drug

    Brigatinib

    go.drugbank.com/drugs/DB12267
    ApprovedInvestigational

    It presents selectivity against the mutant forms of EGFR compared to the wild-type.

  6. Drug

    Safrazine

    go.drugbank.com/drugs/DB09253
    ApprovedWithdrawn

    Safrazine is a member of the hydrazine family with non-selective and irreversible inhibitor effects against monoamine oxidases. In 1960, it was used as an antidepressant but it is now discontinued.

    Categories: Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome
  7. Drug

    Osimertinib

    go.drugbank.com/drugs/DB09330
    ApprovedInvestigational

    Approximately 10% of patients with NSCLC have a rapid and clinically effective response to EGFR-TKIs due to the presence of specific activating EGFR mutations within the tumour cells. … [A7927] More specifically, deletions around the LREA motif in exon 19 and exon 21 L858R point mutations are correlated with response to therapy.

  8. Drug

    Inbakicept

    go.drugbank.com/drugs/DB16479
    Investigational

    It is one of the active ingredients in Anktiva, a combination product also containing [nogapendekin alfa], where a single inbakicept is complexed with two nogapendekin alfa components.

  9. Drug

    Dehydroascorbic acid

    go.drugbank.com/drugs/DB08830
    Experimental

    Currently dehydroascorbic acid is an experimental drug with no known approved indications. … This reaction is reversible, but dehydroascorbic acid can instead undergo irreversible hydrolysis to 2,3-diketogulonic acid.

  10. Drug

    Benzhydrocodone

    go.drugbank.com/drugs/DB15465
    Approved

    [L4894] It was developed in an effort to reduce parenteral bioavailability of the active metabolite as a deterrent to abuse.